Literature DB >> 16702489

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Sidney C Smith, Jerilyn Allen, Steven N Blair, Robert O Bonow, Lawrence M Brass, Gregg C Fonarow, Scott M Grundy, Loren Hiratzka, Daniel Jones, Harlan M Krumholz, Lori Mosca, Richard C Pasternak, Thomas Pearson, Marc A Pfeffer, Kathryn A Taubert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16702489     DOI： 10.1161/CIRCULATIONAHA.106.174516

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  377 in total

1.  Influence of education and working background on physicians' knowledge of secondary prevention guidelines for coronary heart disease: results from a survey in China.

Authors:  Yan-Jun Gong; Tao Hong; Jie Jiang; Rong-Hui Yu; Yan Zhang; Zhao-Ping Liu; Yong Huo
Journal:  J Zhejiang Univ Sci B       Date:  2012-03       Impact factor: 3.066

2.  Aspirin for the primary prevention of cardiovascular diseases.

Authors:  Ludovica Tagliabue; Franca Dipaola; Francesca Perego; Gian Marco Podda
Journal:  Intern Emerg Med       Date:  2012-06-06       Impact factor: 3.397

3.  Therapy: raising HDL cholesterol levels: a flight of Icarus?

Authors:  Gian Paolo Rossi; Damiano Rizzoni
Journal:  Nat Rev Endocrinol       Date:  2010-05       Impact factor: 43.330

4.  The heart of new ulm: a vision for the future.

Authors:  Jackie L Boucher; Raquel Franzini Pereira; Kevin J Graham; Richard R Pettingill; James V Toscano; Timothy D Henry
Journal:  J Cardiovasc Transl Res       Date:  2008-10-17       Impact factor: 4.132

5.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

6.  Adherence to treatment guidelines and therapeutic regimens: a US claims-based benchmark of a commercial population.

Authors:  C Ron Cantrell; Julie L Priest; Christopher L Cook; Jack Fincham; Steven P Burch
Journal:  Popul Health Manag       Date:  2010-12-13       Impact factor: 2.459

7.  Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?

Authors:  David J Maron; William E Boden; William S Weintraub; Karen J Calfas; Robert A O'Rourke
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-02

8.  Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines.

Authors:  Renee Stark; Inge Kirchberger; Matthias Hunger; Margit Heier; Reiner Leidl; Wolfgang von Scheidt; Christa Meisinger; Rolf Holle
Journal:  Clin Res Cardiol       Date:  2013-11-28       Impact factor: 5.460

9.  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.

Authors:  Vasilios G Athyros; Anna I Kakafika; Athanasios A Papageorgiou; Konstantinos Tziomalos; Athanasios Skaperdas; Efstathios Pagourelias; Athina Pirpasopoulou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lipids       Date:  2007-08-23       Impact factor: 1.880

Review 10.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.